Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, presented today findings from its novel human-in-mouse (HIM) tissue transgenic cancer model system, in which AVEO successfully created invasive human tumors that develop over time in mice from primary human breast tissue. This model enables scientists, for the first time, to generate and study in vivo, human tumor initiation, progression and treatment in a preclinical model. This groundbreaking model was presented today in a session entitled "Mouse Models of Cancer 6: Signaling Mechanisms in Initiation, Progression and Therapeutics" at the 100th American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, California.

"For decades, human cancer cell line-derived xenografts have been the in vivo models of choice for pre-clinical studies, and with a few notable exceptions, those xenograft models have not been predictive of human clinical efficacy," said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. "As a result, clinical development in oncology remains largely empirical, resulting in a greater than 90 percent failure rate and long development timelines with significant capital risk. We believe our HIM model represents the next generation in modeling that will ultimately revolutionize early clinical development."

Murray O. Robinson, PhD, senior vice president of Translational Research at AVEO, added, "One issue with cell line xenografts is that the cell culture conditions for establishing cancer cell lines impart strong selection pressures that are different from those experienced by cells in an in vivo environment. Our proprietary models as part of the Human Response Prediction(TM) Platform provide a defined genetic context as well as an accurate tissue context in which to validat
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... Idaho , Jan. 23, 2015  Now available for ... No. 7,849,611) support that prevents ankle sprains by cushioning ... brace, it fits securely around the outside of any ... mobility & comfort while still offering protection against sprains. ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ... ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, Schedule ... ) today, and provides an update for shareholders detailing why ... is requested. Dear Shareholders, As we ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... April 09, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced ... 2 trial of the triplet combination of ... be,presented at the 98th annual meeting of ... Los Angeles. Preclinical studies of,cellular and molecular ...
... BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - ... that scientists from the company will present ... seliciclib, the company's,most advanced drug candidates in ... two poster presentations during the upcoming,Annual Meeting ...
Cached Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 2Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 3Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 4
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for ... its latest collection of wedding dresses , and launches ... is the wedding dress on your big day; the wedding ... Every bride wants to find the most suitable wedding dress. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the ... year ended December 31, 2008. For the three months ended ... decrease from revenues of $389,000 in the prior year period, ... as compared with net income of $38,000 ($0.01 per share) ...
... ordered to pay restitution of $2.3 billion and forfeit ... Financial Enterprises (NCFE) executives were sentenced today for their ... financial health of NCFE, Acting Assistant Attorney General Rita ... the Southern District of Ohio announced. NCFE, formerly based ...
... University Medical Center at Princeton ( ... at all levels -- emergency, inpatient and neonatal ... Children,s Hospital of Philadelphia (CHOP).(Photo: http://www.newscom.com/cgi-bin/prnh/20090327/NY90350 ... hospitals and research facilities in the world, is ranked ...
... The Kroger Co. (NYSE: KR ) said ... in its family of retail stores because the product ... names in the 31 states where Kroger operates are ... Fry,s, King Soopers, Smith,s, Dillons, QFC, City Market, Foods ...
... Barkin, Basin Dog Park on April 1 ST. JOSEPH, Mo., ... Vegas will find that getting their pets, hearts checked is ... Mobile Dog Heart Health Tour will make its first ... the Barkin, Basin Dog Park to perform free heart examinations ...
... and TOKYO, March 27 Chiltern International Limited (Chiltern), ... development and staffing services in Europe, the Americas and ... (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co. ... the Asian region, have jointly organized a seminar in ...
Cached Medicine News:Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 3Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 4Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 5Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 3Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 4Health News:University Medical Center at Princeton to Enhance Pediatric Care Through Agreement with The Children's Hospital of Philadelphia 2Health News:Kroger Recalls Shelled Pistachios Due to Possible Health Risk 2Health News:Mobile Dog Heart Health Tour Kicks off in Las Vegas to Provide Free Heart Examinations in Sound-Proof Setting 2Health News:Mobile Dog Heart Health Tour Kicks off in Las Vegas to Provide Free Heart Examinations in Sound-Proof Setting 3Health News:Chiltern and EPS International Hold a Joint Seminar in Tokyo, Japan 2Health News:Chiltern and EPS International Hold a Joint Seminar in Tokyo, Japan 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: